
William D Tap

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1331035/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	21.4	2,702
2	Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncology, The, 2018, 19, 416-426.	10.7	517
3	Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet, The, 2016, 388, 488-497.	13.7	512
4	PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nature Genetics, 2014, 46, 1227-1232.	21,4	472
5	Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 536-563.	4.9	457
6	Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. New England Journal of Medicine, 2015, 373, 428-437.	27.0	438
7	Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. Cancer Discovery, 2018, 8, 944-957.	9.4	313
8	Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome. American Journal of Surgical Pathology, 2017, 41, 941-949.	3.7	278
9	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet, The, 2019, 394, 478-487.	13.7	273
10	Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Human Pathology, 2015, 46, 357-365.	2.0	252
11	Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With <i>CDK4</i> Inhibitor Palbociclib. JAMA Oncology, 2016, 2, 937.	7.1	241
12	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	28.9	223
13	Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncology, The, 2017, 18, 1089-1103.	10.7	214
14	Phase II Study of Ganitumab, a Fully Human Anti–Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients With Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors. Journal of Clinical Oncology, 2012, 30, 1849-1856.	1.6	198
15	Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas. JAMA - Journal of the American Medical Association, 2020, 323, 1266.	7.4	190
16	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncology, The, 2020, 21, 935-946.	10.7	186
17	NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. American Journal of Surgical Pathology, 2018, 42, 791-798.	3.7	182
18	Outcomes and Toxicity for Hypofractionated and Single-Fraction Image-Guided Stereotactic Radiosurgery for Sarcomas Metastasizing to the Spine. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1085-1091.	0.8	131

#	Article	IF	CITATIONS
19	Longâ€ŧerm results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with highâ€grade, operable osteosarcoma. Cancer, 2012, 118, 5888-5893.	4.1	127
20	Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma. Clinical Cancer Research, 2014, 20, 4200-4209.	7.0	127
21	Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab. JAMA Oncology, 2020, 6, 402.	7.1	125
22	The epigenomics of sarcoma. Nature Reviews Cancer, 2020, 20, 608-623.	28.4	121
23	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clinical Cancer Research, 2017, 23, 2972-2980.	7.0	106
24	Combined Inhibition of MAP Kinase and KIT Signaling Synergistically Destabilizes ETV1 and Suppresses GIST Tumor Growth. Cancer Discovery, 2015, 5, 304-315.	9.4	102
25	Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 319-330.e1.	0.8	96
26	Ultraâ€rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer, 2021, 127, 2934-2942.	4.1	96
27	Utilization of positron emission tomography in the management of patients with sarcoma. Current Opinion in Oncology, 2009, 21, 345-351.	2.4	95
28	Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. Modern Pathology, 2020, 33, 591-602.	5.5	87
29	Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTs. Clinical Cancer Research, 2014, 20, 3146-3158.	7.0	86
30	Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. Journal of Clinical Oncology, 2020, 38, 1693-1701.	1.6	86
31	MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma. Molecular Cancer Therapeutics, 2015, 14, 395-406.	4.1	83
32	Patient-reported Symptoms of Tenosynovial Giant Cell Tumors. Clinical Therapeutics, 2016, 38, 778-793.	2.5	79
33	Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. European Journal of Cancer, 2021, 145, 132-142.	2.8	75
34	Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results. JAMA Oncology, 2017, 3, 944.	7.1	73
35	Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. Investigational New Drugs, 2020, 38, 433-444.	2.6	69
36	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nature Communications, 2022, 13, .	12.8	63

#	Article	IF	CITATIONS
37	Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras. Annals of Surgery, 2021, 273, 128-138.	4.2	62
38	Genomic Profiling Identifies Association of <i>IDH1/IDH2</i> Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma. Clinical Cancer Research, 2020, 26, 419-427.	7.0	60
39	Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome. Annals of Surgical Oncology, 2017, 24, 3972-3980.	1.5	59
40	Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing. Clinical Cancer Research, 2020, 26, 3881-3888.	7.0	59
41	Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors. Annals of Surgery, 2018, 268, 296-302.	4.2	58
42	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. Journal of Clinical Oncology, 2021, 39, 3128-3139.	1.6	56
43	NTRK3 overexpression in undifferentiated sarcomas with YWHAE and BCOR genetic alterations. Modern Pathology, 2020, 33, 1341-1349.	5.5	53
44	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nature Communications, 2022, 13, .	12.8	51
45	Locally Aggressive Connective Tissue Tumors. Journal of Clinical Oncology, 2018, 36, 202-209.	1.6	48
46	Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO–Friends of Cancer Research Joint Research Statement. Clinical Cancer Research, 2021, 27, 2394-2399.	7.0	47
47	PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence. Oncogene, 2018, 37, 5066-5078.	5.9	38
48	The clinical heterogeneity of round cell sarcomas with <i><scp>EWSR1</scp>/<scp>FUS</scp></i> gene fusions: Impact of gene fusion type on clinical features and outcome. Genes Chromosomes and Cancer, 2020, 59, 525-534.	2.8	35
49	Molecular Subtypes of Uterine Leiomyosarcoma and Correlation with Clinical Outcome. Neoplasia, 2015, 17, 183-189.	5.3	33
50	Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastases. Spine Journal, 2016, 16, 291-298.	1.3	32
51	A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. Investigational New Drugs, 2019, 37, 282-290.	2.6	32
52	BCOR upregulation in a poorly differentiated synovial sarcoma with <i>SS18L1‣SX1</i> fusion—A pathologic and molecular pitfall. Genes Chromosomes and Cancer, 2017, 56, 296-302.	2.8	30
53	A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L) Journal of Clinical Oncology, 2018, 36, 11514-11514.	1.6	30
54	Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas. PLoS ONE, 2015, 10, e0133610.	2.5	30

#	Article	IF	CITATIONS
55	Longâ€ŧerm outcomes of pexidartinib in tenosynovial giant cell tumors. Cancer, 2021, 127, 884-893.	4.1	29
56	Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. Oncologist, 2021, 26, e639-e649.	3.7	29
57	ls Repeat Pulmonary Metastasectomy Indicated for Soft Tissue Sarcoma?. Annals of Thoracic Surgery, 2017, 104, 1837-1845.	1.3	28
58	Platelet-derived growth factor receptor-α and -β promote cancer stem cell phenotypes in sarcomas. Oncogenesis, 2018, 7, 47.	4.9	28
59	Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. Oncologist, 2021, 26, e863-e873.	3.7	28
60	Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma Journal of Clinical Oncology, 2017, 35, 11001-11001.	1.6	26
61	A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401) Journal of Clinical Oncology, 2017, 35, 11007-11007.	1.6	26
62	A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas. Oncologist, 2015, 20, 1245-1246.	3.7	25
63	Imaging features and clinical course of undifferentiated round cell sarcomas with CIC-DUX4 and BCOR-CCNB3 translocations. Skeletal Radiology, 2021, 50, 521-529.	2.0	24
64	Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors. JAMA Oncology, 2021, 7, 1343.	7.1	23
65	Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. Clinical Cancer Research, 2021, 27, 3861-3866.	7.0	22
66	Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1 ^{c259} t in HLA-A2 ⁺ patients with synovial sarcoma (NCT01343043) Journal of Clinical Oncology, 2017, 35, 3000-3000.	1.6	20
67	A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma. Clinical Cancer Research, 2022, 28, 1586-1594.	7.0	20
68	Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. , 2022, 10, e004149.		20
69	A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors. Investigational New Drugs, 2021, 39, 1089-1098.	2.6	19
70	Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. JCO Precision Oncology, 2020, 4, 1350-1360.	3.0	18
71	Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-11± inhibition, and hypoxia-activated chemotherapy. Oncotarget, 2016, 7, 42844-42858.	1.8	18
72	Phosphoproteomic Profiling Reveals IL6-Mediated Paracrine Signaling within the Ewing Sarcoma Family of Tumors. Molecular Cancer Research, 2014, 12, 1740-1754.	3.4	17

#	Article	IF	CITATIONS
73	Gemcitabine kills proliferating endothelial cells exclusively via acid sphingomyelinase activation. Cellular Signalling, 2017, 34, 86-91.	3.6	16
74	A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST) Journal of Clinical Oncology, 2015, 33, 10507-10507.	1.6	16
75	Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT) Journal of Clinical Oncology, 2018, 36, 11502-11502.	1.6	16
76	A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. Oncologist, 2019, 24, 857-863.	3.7	15
77	The measurement of physical functioning among patients with Tenosynovial Giant Cell Tumor (TGCT) using the Patient-Reported Outcomes Measurement Information System (PROMIS). Journal of Patient-Reported Outcomes, 2019, 3, 6.	1.9	14
78	Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor. Molecular Cancer Research, 2021, 19, 1146-1155.	3.4	14
79	Psychosocial Needs and Preferences for Care among Adolescent and Young Adult Cancer Patients (Ages 15–39): A Qualitative Study. Cancers, 2022, 14, 710.	3.7	14
80	Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. Monthly Notices of the Royal Astronomical Society: Letters, 2021, 92, 493-499.	3.3	13
81	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 2022, 40, 997-1008.	1.6	13
82	Comprehensive genomic profiling of EWSR1/FUS::CREB translocation-associated tumors uncovers prognostically significant recurrent genetic alterations and methylation-transcriptional correlates. Modern Pathology, 2022, 35, 1055-1065.	5.5	13
83	HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome. Clinical Cancer Research, 2020, 26, 5448-5455.	7.0	12
84	Pilot study of NY-ESO-1 ^{c259} T cells in advanced myxoid/round cell liposarcoma Journal of Clinical Oncology, 2018, 36, 3005-3005.	1.6	12
85	A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma Journal of Clinical Oncology, 2019, 37, 11049-11049.	1.6	12
86	Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT. Clinical Cancer Research, 2022, 28, 298-307.	7.0	12
87	Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma. Cancer Chemotherapy and Pharmacology, 2019, 83, 191-199.	2.3	10
88	Prognostic Factors After Neoadjuvant Imatinib for Newly Diagnosed Primary Gastrointestinal Stromal Tumor. Journal of Gastrointestinal Surgery, 2021, 25, 1828-1836.	1.7	10
89	Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations. OncoTargets and Therapy, 2022, Volume 15, 53-66.	2.0	10
90	Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma. Clinical Cancer Research, 2022, 28, 939-947.	7.0	10

#	Article	IF	CITATIONS
91	Establishing a Mutually Respectful Environment in the Workplace: A Toolbox for Performance Excellence. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e219-e226.	3.8	9
92	A novel image-based system for risk stratification in patients with desmoplastic small round cell tumor. Journal of Pediatric Surgery, 2020, 55, 376-380.	1.6	9
93	Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors. Journal of Clinical Pharmacology, 2021, 61, 480-492.	2.0	8
94	Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot. Cancer Medicine, 2021, 10, 4221-4227.	2.8	8
95	Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance) Tj ETQq1 1	0.784314 1.6	rgBT /Overl
96	A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST) Journal of Clinical Oncology, 2018, 36, 11509-11509.	1.6	8
97	Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial. Journal of Geriatric Oncology, 2020, 11, 463-469.	1.0	7
98	Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1422-1432.	2.5	7
99	A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic sarcoma Journal of Clinical Oncology, 2018, 36, 11516-11516.	1.6	6
100	Pilot study of NKTR214 and nivolumab in patients with sarcomas Journal of Clinical Oncology, 2019, 37, 11010-11010.	1.6	6
101	Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors Molecular and Cellular Oncology, 2018, 5, e1384882.	0.7	5
102	Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS) Journal of Clinical Oncology, 2017, 35, TPS11081-TPS11081.	1.6	5
103	GeDDiS: insight into frontline therapy in soft tissue sarcoma. Lancet Oncology, The, 2017, 18, 1297-1299.	10.7	4
104	Incidence and Management of Olaratumab Infusion-Related Reactions. Journal of Oncology Practice, 2019, 15, e925-e933.	2.5	4
105	CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden. Future Oncology, 2022, , .	2.4	4
106	Al-Radiomics Can Improve Inclusion Criteria and Clinical Trial Performance. Tomography, 2022, 8, 341-355.	1.8	4
107	<i><scp>FGFR2</scp>::<scp>TACC2</scp></i> fusion as a novel <scp>KIT</scp> â€independent mechanism of targeted therapy failure in a multidrugâ€resistant gastrointestinal stromal tumor. Genes Chromosomes and Cancer, 2022, 61, 412-419.	2.8	4
108	Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma. Clinical Cancer Research, 2022, 28, 2579-2586.	7.0	4

#	Article	IF	CITATIONS
109	Safety and Efficacy of Hepatic Artery Embolization in Treating Solitary Fibrous Tumor Metastatic to the Liver. Sarcoma, 2019, 2019, 1-6.	1.3	3
110	Multidisciplinary care in tenosynovial giant cell tumours. Lancet Oncology, The, 2019, 20, 755-756.	10.7	3
111	The clinical impact of performing routine next generation sequencing (NGS) in gastrointestinal stromal tumors (GIST) Journal of Clinical Oncology, 2017, 35, 11010-11010.	1.6	3
112	Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2022, 28, 1507-1517.	7.0	3
113	Effect of Mild and Moderate Hepatic Impairment (Defined by Child–Pugh Classification and National) Tj ETQq1 ∷ Journal of Clinical Pharmacology, 2022, 62, 992-1005.	1 0.78431 2.0	4 rgBT /Ove 3
114	TOMAS: revisiting PARP inhibitor combination therapy. Lancet Oncology, The, 2018, 19, 1269-1270.	10.7	2
115	Li-Fraumeni Syndrome-related Malignancies Involving the Genitourinary Tract: Review of a Single-institution Experience. Urology, 2018, 119, 55-61.	1.0	2
116	Analysis of the Chemotherapy-Free Interval following Image-Guided Ablation in Sarcoma Patients. Sarcoma, 2020, 2020, 1-8.	1.3	2
117	Tumor volume score (TVS), modified recist, and tissue damage score (TDS) as novel methods for assessing response in tenosynovial giant cell tumors (TGCT) treated with pexidartinib: Relationship with patient-reported outcomes (PROs) Journal of Clinical Oncology, 2017, 35, 11048-11048.	1.6	2
118	Risk factors associated with ifosfamide (IFOS)-induced encephalopathy in patients (pts) with metastatic (Met) sarcoma (Sarc) Journal of Clinical Oncology, 2017, 35, e22518-e22518.	1.6	1
119	TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma Journal of Clinical Oncology, 2018, 36, TPS11590-TPS11590.	1.6	1
120	A phase lb study of BGJ398 in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST) Journal of Clinical Oncology, 2017, 35, 11039-11039.	1.6	0
121	Subgroup analysis of elderly patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial Journal of Clinical Oncology, 2018, 36, 11575-11575.	1.6	0
122	Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS) Journal of Clinical Oncology, 2018, 36, e23570-e23570.	1.6	0
123	Clinical features and outcomes of secondary somatic malignancy (SSM) associated with primary mediastinal nonseminomatous germ cell tumors (PM-NSGCT) Journal of Clinical Oncology, 2019, 37, 531-531.	1.6	0
124	Clinical features and outcomes of secondary somatic malignancy (SSM) arising from teratoma in late relapse germ cell tumor (GCT) Journal of Clinical Oncology, 2019, 37, 518-518.	1.6	0
125	Enhancement of Soft Tissue Sarcoma Response to Gemcitabine through Timed Administration of a Short-Acting Anti-Angiogenic Agent. Cellular Physiology and Biochemistry, 2020, 54, 707-718.	1.6	0